HUANG Qin, MA Yu-nan. In vitro-in vivo correlation (IVIVC):perspectives from CDE reviewer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 961-964.
1 USP 28-NF 23, General Charpters :<1088> In Vitro And In Vivo Evaluation Of Dosage Forms [M].2005. 2 FDA.Guidance for Industry :Extended Release Oral Dosage Forms:Development, Evaluation, and Application of In Vitro In Vivo Correlations [EB].September.1997.http : www.fda. gov cder guidance 1306fnl.pdf 3 FDA.Guidance for Industry :Scale up and Post Approval Changes-Immediate Release (SUPAC-IR) [EB].November.1995. http: www.fda.gov cder guidance cmc5.pdf 4 FDA.Guidance for Industry :Scale up and Post Approval Changes-Modified Release (SUPAC-MR) [EB].Oct.1997.http: www.fda.gov cder guidance 1214fnl.pdf 5 FDA.Guidance for Industry :Dissolution Testing of Immediate Release Solid Dosage Forms [EB].August.1997.http: www. fda.gov cder guidance 1713bp1.pdf 6 FDA.Guidance for Industry :Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations [EB].March.2003.http: www.fda.gov cder guidance 5356fnl.pdf 7 FDA.Guidance for Industry :Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification Sy stem [EB].August.2000.http: www.fda.gov cder guidance 3618fnl.pdf
